Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02973269 · ClinicalTrials.gov registry record · Phase 2
DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis
A Phase 2 study, sponsored by Revance Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT02973269 is a Phase 2 study that was terminated before completion, run by Revance Therapeutics. The registered enrollment target is 7 participants.
The verdict
NCT02973269, a Phase 2 study, was terminated before completion, sponsored by Revance Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
The specific aim of the study is to compare the safety and efficacy of a single administration of DaxibotulinumtoxinA for Injection versus placebo for managing plantar fasciitis.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL daxibotulinumtoxin type A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2016-11-14 |
| Est. Completion | 2017-05-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02973269
The ClinicalTrials.gov registry entry for NCT02973269 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Revance Therapeutics, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02973269 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02973269 about?
NCT02973269 is a clinical study titled "DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis". The specific aim of the study is to compare the safety and efficacy of a single administration of DaxibotulinumtoxinA for Injection versus placebo for managing plantar fasciitis.
What is the current status of trial NCT02973269?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2016-11-14. Estimated completion is 2017-05-31.
What interventions are being tested in trial NCT02973269?
The interventions under investigation include: Placebo (BIOLOGICAL), daxibotulinumtoxin type A (BIOLOGICAL).
Who is sponsoring clinical trial NCT02973269?
This trial is sponsored by Revance Therapeutics, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.